Peking University: Neoplasms trials

The registry lists 14 Neoplasms studies with Peking University as lead sponsor. 6 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 9Phase 2 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous AdenocarcinomaNot yet recruitingNCT07454031Phase 1
• MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid TumorsRecruitingNCT06170294Phase 1
• Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid TumorNot yet recruitingNCT05933668Phase 1
• RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid TumorsNot yet recruitingNCT05284968Early Phase 1
• Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingNCT05165407Phase 2
• JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid TumorsRecruitingNCT04280341Phase 1
• UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsStatus unknownNCT05775666Phase 1
• Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid TumorsStatus unknownNCT05730361Phase 1
• MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational StudyStatus unknownNCT04500990
• KN026 Combined With KN046 in Subjects With HER2 Positive Solid TumorCompletedNCT04040699Phase 1
• Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid TumorsStatus unknownNCT03879057Phase 1
• Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.CompletedNCT03874897Phase 1
• Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid TumorsStatus unknownNCT03596593Not applicable
• Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine NeoplasmsStatus unknownNCT03288597